MedTrace Logo

A Randomised Trial of ATRA in a Novel Drug Combination for Pancreatic Cancer

NCT04241276 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 170

Last updated 2026-01-07

No results posted yet for this study

Summary

This is an open-label, multi-centre, randomised, stratified, phase IIb clinical trial of ATRA administered in combination with gemcitabine and nab-paclitaxel in patients with laPDAC.

Conditions

Interventions

DRUG

ATRA

45 mg/m2 orally (in two divided doses) from days 1 to 15 of each cycle

DRUG

Gemcitabine

1000mg/m2 IV on days 1, 8 and 15 of a 28 day cycle

DRUG

nab-paclitaxel

125mg/m2 IV on days 1, 8 and 15 of a 28 day cycle

Sponsors & Collaborators

  • Medical Research Council

    collaborator OTHER_GOV

  • Celgene

    collaborator INDUSTRY

  • Queen Mary University of London

    lead OTHER

Principal Investigators

  • Hemant Kocher, Professor · Queen Mary University of London

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2028-06-29
Completion
2029-02-28

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04241276 on ClinicalTrials.gov